Seth Loring Harrison, Director at Akero Therapeutics, Inc. (AKRO), sold 46,262 shares at $46.44 ($2.2M) on 2022-11-30, disclosed to the SEC on 2022-12-02.
Open-market sale of $2.2M AKRO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.44 | 6,851 | $318K | 14.7% |
| 2 | $46.44 | 6,322 | $294K | 13.5% |
| 3 | $46.44 | 6,322 | $294K | 13.5% |
| 4 | $46.44 | 6,851 | $318K | 14.7% |
| 5 | $47.60 | 4,779 | $227K | 10.5% |
| 6 | $47.60 | 4,779 |
| $227K |
| 10.5% |
| 7 | $47.60 | 5,179 | $247K | 11.4% |
| 8 | $47.60 | 5,179 | $247K | 11.4% |
| Total | $46.94 avg | 46,262 | $2.2M | 100% |
| Filing → |
| STOK | BUY | 2020-11-25 | $14.6M | — | Filing → |
| AKRO | BUY | 2020-07-14 | $14.9M | — | Filing → |
| AKRO | BUY | 2019-06-25 | $14.4M | — | Filing → |